Dasatinib in Treating Patients with Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Solar Melanoma that Cannot Be Removed by Surgery

Study Type: Interventional

Age/Sex Requirement: 18 years+ (None)

Sponsor: Eastern Cooperative Oncology Group

ClinicalTrials.gov Identifier: NCT00700882

Purpose: To study how well dasatinib works in treating patients with locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery. The primary outcome measure is objective tumor response rate. Secondary outcomes measures include response duration, progression-free survival, and safety profile.

Click here for more information about the clinical trial.